Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 1

Status

Completed 12Recruiting 8Unknown 4Active not recruiting 4Approved for marketing 3Terminated 2Not yet recruiting 1

Sponsor Class

OTHER 5INDUSTRY 4NETWORK 1

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 4

Conditions

Carcinoma, Non-Small-Cell Lung 299Neoplasms 179Breast Neoplasms 172Colorectal Neoplasms 107Neoplasm Metastasis 101Melanoma 99Multiple Myeloma 91Prostatic Neoplasms 90Ovarian Neoplasms 83Recurrence 79Carcinoma, Renal Cell 73Lung Neoplasms 71Stomach Neoplasms 67Squamous Cell Carcinoma of Head and Neck 67Lymphoma, Non-Hodgkin 60Pancreatic Neoplasms 59Leukemia, Lymphocytic, Chronic, B-Cell 56Leukemia, Myeloid, Acute 54Carcinoma, Hepatocellular 48Triple Negative Breast Neoplasms 47Small Cell Lung Carcinoma 46Urinary Bladder Neoplasms 45Lymphoma, Large B-Cell, Diffuse 43Head and Neck Neoplasms 41Endometrial Neoplasms 41Lymphoma, Follicular 39Lymphoma 37Uterine Cervical Neoplasms 35Parkinson Disease 4, Autosomal Dominant Lewy Body 35Glioblastoma 34

Interventions

tucatinib 1pertuzumab 1Docetaxel 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Active not recruiting × INDUSTRY × HER2-positive Breast Cancer × Clear all
NCT06445400 2026-05-13

A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 2 Active not recruiting
83 enrolled
Breast

HER2-positive Breast Cancer

NCT06968585 2026-05-08

A166

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Phase 3 Active not recruiting
365 enrolled
Breast

HER2-positive Breast Cancer

NCT03975647 2026-03-30

A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer

Seagen Inc.

Phase 3 Active not recruiting
466 enrolled 17 charts
Breast

HER2-positive Breast Cancer

NCT06316531 2025-08-19

A Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 3 Active not recruiting
274 enrolled
Breast

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡